Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029
Abstract
The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.
The human microbiome market has been segmented based on product, type, application, disease, and region.
“By application, the therapeutics segment accounted for the largest share of the human microbiome market”
Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.
“By disease, infectious diseases segment accounted for the largest share in the human microbiome market”
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.
“North America: the largest share of the human microbiome market”
North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.
“Asia Pacific: The fastest-growing region in the human microbiome market.”
The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.
The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 60% and Demand Side 40%
•By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%
•By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%
Prominent Players
•Seres Therapeutics, Inc. (US)
•Enterome (France)
•4D pharma plc (UK)
•International Flavors & Fragrances Inc. (US)
•OptiBiotix Health Plc (UK)
•Ferring Pharmaceuticals (Switzerland)
•Synlogic, Inc. (US)
•Second Genome, Inc. (US)
•Vedanta Biosciences, Inc. (US)
•YSOPIA Bioscience (France)
•FlightPath Biosciences, Inc. (US)
•Finch Therapeutics Group, Inc. (US)
•AOBiome Therapeutics (US)
•BioGaia (Sweden)
•Quantbiome, Inc. (dba Ombre) (US)
•Viome Life Sciences, Inc. (US)
•BIOHM Health (US)
•DayTwo (US)
•Atlas Biomed (UK)
•Bione Ventures Private Limited (India)
•Luxia Scientific (France)
•Metabiomics (US)
•Sun Genomics (US)
•Seed Health (US)
•Gnubiotics Sciences (Switzerland)
Research Coverage:
This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
•Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
•Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
•Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.
Content
Table of Contents
1INTRODUCTION25
1.1STUDY OBJECTIVES25
1.2MARKET DEFINITION25
1.2.1INCLUSIONS & EXCLUSIONS25
1.3STUDY SCOPE26
1.4YEARS CONSIDERED26
1.5CURRENCY27
1.6RESEARCH LIMITATIONS27
1.7STAKEHOLDERS27
1.7.1RECESSION IMPACT27
2RESEARCH METHODOLOGY28
2.1RESEARCH DATA28
FIGURE 1HUMAN MICROBIOME MARKET: RESEARCH DESIGN28
2.1.1SECONDARY DATA29
2.1.2PRIMARY DATA29
FIGURE 2HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES30
2.2MARKET ESTIMATION METHODOLOGY30
FIGURE 3MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202331
FIGURE 4HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION)32
FIGURE 5HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029)32
FIGURE 6HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES33
2.3MARKET DATA ESTIMATION AND TRIANGULATION34
2.3.1DATA TRIANGULATION34
FIGURE 7DATA TRIANGULATION METHODOLOGY34
2.4INDUSTRY INSIGHTS35
2.5RESEARCH ASSUMPTIONS35
2.6HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT36
TABLE 1GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)36
TABLE 2US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)36
TABLE 3US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)36
3EXECUTIVE SUMMARY38
FIGURE 8HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)38
FIGURE 9HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)39
FIGURE 10HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)39
FIGURE 11HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT40
4PREMIUM INSIGHTS41
4.1HUMAN MICROBIOME MARKET OVERVIEW41
FIGURE 12RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH41
4.2NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023)41
FIGURE 13THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 202341
4.3HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES42
FIGURE 14BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD42
5MARKET OVERVIEW43
5.1INTRODUCTION43
5.2MARKET DYNAMICS43
FIGURE 15HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES43
TABLE 4HUMAN MICROBIOME MARKET: IMPACT ANALYSIS44
5.2.1DRIVERS44
5.2.1.1Collaborative efforts between microbiome industry and academia for microbiome research44
5.2.1.2Surging demand for personalized medicine45
5.2.1.3Rising awareness about importance of human microbiome45
5.2.2RESTRAINTS46
5.2.2.1Adverse impact of complex regulatory policies on commercialization of microbiomes46
5.2.3OPPORTUNITIES46
5.2.3.1Increased collaboration of key players and small innovative companies to work on new microbiome technologies46
TABLE 5EXAMPLES OF COMPANY DEVELOPMENT47
5.2.4CHALLENGES48
5.2.4.1Slow patient adoption of microbiome-based therapies48
5.2.4.2Complexities involved in development of microbiome therapies48
5.3TECHNOLOGY ANALYSIS49
5.4TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES51
FIGURE 16TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES51
5.5SUPPLY AND VALUE CHAIN ANALYSIS52
5.5.1HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS52
FIGURE 17HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS52
5.5.2VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET53
FIGURE 18HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS53
5.6ECOSYSTEM ANALYSIS54
FIGURE 19HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS54
5.7PORTER’S FIVE FORCES ANALYSIS54
TABLE 6HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS54
5.7.1THREAT OF NEW ENTRANTS54
5.7.2THREAT OF SUBSTITUTES54
5.7.3BARGAINING POWER OF BUYERS55
5.7.4BARGAINING POWER OF SUPPLIERS55
5.7.5INTENSITY OF COMPETITIVE RIVALRY55
5.8REGULATORY ANALYSIS56
5.8.1FDA APPROVALS56
5.8.2REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 7NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 8EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 9ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS57
TABLE 10REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS58
5.9PRICING ANALYSIS58
TABLE 11AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT58
5.9.1AVERAGE SELLING PRICE TREND ANALYSIS58
5.10KEY CONFERENCES AND EVENTS IN 202359
5.10.1HUMAN MICROBIOME CONFERENCES (2023)59
TABLE 12HUMAN MICROBIOME CONFERENCES (2023)59
5.11KEY STAKEHOLDERS AND BUYING CRITERIA60
5.11.1KEY STAKEHOLDERS IN BUYING PROCESS60
FIGURE 20HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS60
5.11.2HUMAN MICROBIOME MARKET: BUYING CRITERIA60
FIGURE 21KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS60
6HUMAN MICROBIOME MARKET, BY APPLICATION61
6.1INTRODUCTION62
TABLE 13HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)62
6.2THERAPEUTICS62
6.2.1AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET62
TABLE 14HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION)64
TABLE 15NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)64
TABLE 16EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)64
TABLE 17ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)65
6.3DIAGNOSTICS65
6.3.1INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET65
TABLE 18HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION)66
TABLE 19NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)66
TABLE 20EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)67
TABLE 21ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)67
7HUMAN MICROBIOME MARKET, BY DISEASE68
7.1INTRODUCTION69
TABLE 22HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)69
7.2INFECTIOUS DISEASES69
7.2.1RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET69
TABLE 23DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES70
TABLE 24HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION)71
TABLE 25NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)71
TABLE 26EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)71
TABLE 27ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)72
7.3GASTROINTESTINAL DISEASES72
7.3.1SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET72
TABLE 28HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)72
TABLE 29NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
TABLE 30EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
TABLE 31ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
7.4ENDOCRINE & METABOLIC DISORDERS74
7.4.1DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET74
TABLE 32DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS74
TABLE 33HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION)75
TABLE 34NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)75
TABLE 35EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)75
TABLE 36ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)76
7.5CANCER76
7.5.1DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET76
TABLE 37HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)77
TABLE 38NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)77
TABLE 39EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)77
TABLE 40ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)78
7.6OTHER DISEASES78
TABLE 41HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION)78
TABLE 42NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)78
TABLE 43EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)79
TABLE 44ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)79
8HUMAN MICROBIOME MARKET, BY PRODUCT80
8.1INTRODUCTION81
TABLE 45HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION))81
8.2DRUGS81
8.2.1GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET81
TABLE 46HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)82
TABLE 47NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)82
TABLE 48EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)82
TABLE 49ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)83
8.3DIAGNOSTIC TESTS83
8.3.1GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET83
TABLE 50HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION)84
TABLE 51NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)84
TABLE 52EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)85
TABLE 53ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)85
8.4PROBIOTICS85
8.4.1GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY85
TABLE 54HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION)86
TABLE 55NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)86
TABLE 56EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)87
TABLE 57ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)87
8.5PREBIOTICS87
8.5.1DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH87
TABLE 58HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION)88
TABLE 59NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)88
TABLE 60EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)89
TABLE 61ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)89
8.6OTHER PRODUCTS89
TABLE 62HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION)90
TABLE 63NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)90
TABLE 64EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)90
TABLE 65ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)91
9HUMAN MICROBIOME MARKET, BY TYPE92
9.1INTRODUCTION93
TABLE 66HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)93
9.2BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)93
9.2.1ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH93
TABLE 67HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION)94
TABLE 68NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)94
TABLE 69EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)94
TABLE 70ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)95
9.3PEPTIDES95
9.3.1POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET95
TABLE 71HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION)96
TABLE 72NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)96
TABLE 73EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)96
TABLE 74ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)97
9.4LIVE BIOTHERAPEUTIC PRODUCTS97
9.4.1GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET97
TABLE 75HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION)98
TABLE 76NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)98
TABLE 77EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)98
TABLE 78ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)99
9.5OTHER TYPES99
TABLE 79HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION)99
TABLE 80NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
TABLE 81EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
TABLE 82ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
10HUMAN MICROBIOME MARKET, BY REGION101
10.1INTRODUCTION102
FIGURE 22HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)102
TABLE 83HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION)102
10.2NORTH AMERICA103
FIGURE 23NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT104
TABLE 84NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)104
TABLE 85NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)105
TABLE 86NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)105
TABLE 87NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)105
10.2.1US106
10.2.1.1Spike in research activities to drive market106
TABLE 88US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)106
TABLE 89US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)107
TABLE 90US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)107
TABLE 91US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)107
10.2.2CANADA108
10.2.2.1Rising prevalence of chronic diseases to boost microbiome research108
TABLE 92CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)108
TABLE 93CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)108
TABLE 94CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)109
TABLE 95CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)109
10.2.3NORTH AMERICA: RECESSION IMPACT109
10.3EUROPE110
TABLE 96EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)110
TABLE 97EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)111
TABLE 98EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)111
TABLE 99EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)111
10.3.1GERMANY112
10.3.1.1Rapid increase in government funding to propel market112
TABLE 100GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)112
TABLE 101GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)112
TABLE 102GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)113
TABLE 103GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)113
10.3.2UK113
10.3.2.1Significant government investments in genomics research to propel growth113
TABLE 104UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)114
TABLE 105UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)114
TABLE 106UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)114
TABLE 107UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)115
10.3.3FRANCE115
10.3.3.1Rise in microbiome sequencing startups to boost growth115
TABLE 108HUMAN MICROBIOME STARTUPS IN FRANCE116
TABLE 109FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)116
TABLE 110FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)117
TABLE 111FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)117
TABLE 112FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)117
10.3.4REST OF EUROPE118
TABLE 113REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)118
TABLE 114REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)118
TABLE 115REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)119
TABLE 116REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)119
10.3.5EUROPE: IMPACT OF RECESSION119
10.4ASIA PACIFIC120
FIGURE 24ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT121
TABLE 117ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)121
TABLE 118ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)122
TABLE 119ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)122
TABLE 120ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)122
TABLE 121ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)123
10.4.1CHINA123
10.4.1.1Increasing R&D investments to drive growth123
TABLE 122CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)124
TABLE 123CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)124
TABLE 124CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)124
TABLE 125CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)125
10.4.2JAPAN125
10.4.2.1Growing geriatric population to present opportunities for market growth125
TABLE 126JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)126
TABLE 127JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)126
TABLE 128JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)126
TABLE 129JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)127
10.4.3INDIA127
10.4.3.1Increasing prevalence of chronic diseases to support growth127
TABLE 130INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)128
TABLE 131INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)128
TABLE 132INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)128
TABLE 133INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)129
10.4.4REST OF ASIA PACIFIC129
TABLE 134REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)129
TABLE 135REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)130
TABLE 136REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)130
TABLE 137REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)130
10.4.5ASIA PACIFIC: RECESSION IMPACT131
10.5REST OF THE WORLD131
TABLE 138REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)131
TABLE 139REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)132
TABLE 140REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)132
TABLE 141REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)132
10.5.1REST OF THE WORLD: RECESSION IMPACT133
11COMPETITIVE LANDSCAPE134
11.1INTRODUCTION134
11.2KEY STRATEGIES ADOPTED BY PLAYERS134
FIGURE 25HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS135
11.3COMPANY EVALUATION QUADRANT136
FIGURE 26HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022)137
11.3.1STARS138
11.3.2EMERGING LEADERS138
11.3.3PERVASIVE PLAYERS138
11.3.4PARTICIPANTS138
11.4COMPANY EVALUATION QUADRANT: START-UPS/SMES139
11.4.1PROGRESSIVE COMPANIES139
11.4.2STARTING BLOCKS139
11.4.3RESPONSIVE COMPANIES139
11.4.4DYNAMIC COMPANIES139
FIGURE 27HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)140
11.4.5COMPETITIVE BENCHMARKING141
11.4.5.1Human microbiome market: Detailed list of start-ups/SMEs141
TABLE 142HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES141
11.4.5.2Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs)142
TABLE 143HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)142
11.5COMPETITIVE SCENARIO AND TRENDS142
TABLE 144HUMAN MICROBIOME MARKET: DEALS142
11.5.1PRODUCT LAUNCHES144
TABLE 145HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES144
11.5.2EXPANSIONS144
TABLE 146HUMAN MICROBIOME MARKET: EXPANSIONS144
12COMPANY PROFILES145
(Business overview, Products offered, Recent Developments, MNM view)*
12.1KEY PLAYERS145
12.1.1SERES THERAPEUTICS, INC.145
TABLE 147SERES THERAPEUTICS, INC.: COMPANY OVERVIEW145
12.1.2ENTEROME148
TABLE 148ENTEROME: COMPANY OVERVIEW148
12.1.34D PHARMA PLC151
TABLE 1494D PHARMA: COMPANY OVERVIEW151
FIGURE 294D PHARMA: COMPANY SNAPSHOT (2022)151
12.1.4INTERNATIONAL FLAVORS & FRAGRANCES, INC.154
TABLE 150INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW154
FIGURE 30INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)155
12.1.5OPTIBIOTIX HEALTH PLC157
TABLE 151OPTIBIOTIX: COMPANY OVERVIEW157
FIGURE 31OPTIBIOTIX: COMPANY SNAPSHOT (2021)158
12.1.6FERRING PHARMACEUTICALS162
TABLE 152FERRING PHARMACEUTICALS: COMPANY OVERVIEW162
12.1.7SYNLOGIC, INC.163
TABLE 153SYNLOGIC, INC.: COMPANY OVERVIEW163
FIGURE 32SYNLOGIC, INC: COMPANY SNAPSHOT (2022)163
12.1.8SECOND GENOME INC.165
TABLE 154SECOND GENOME INC.: COMPANY OVERVIEW165
12.1.9VEDANTA BIOSCIENCES, INC.167
TABLE 155VEDANTA BIOSCIENCES: COMPANY OVERVIEW167
12.1.10YSOPIA BIOSCIENCE169
TABLE 156YSOPIA BIOSCIENCE: COMPANY OVERVIEW169
12.1.11FLIGHTPATH BIOSCIENCES, INC.170
TABLE 157FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW170
12.1.12FINCH THERAPEUTICS GROUP, INC.171
TABLE 158FINCH THERAPEUTICS: COMPANY OVERVIEW171
FIGURE 33FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)171
12.1.13AOBIOME THERAPEUTICS172
TABLE 159AOBIOME THERAPEUTICS: COMPANY OVERVIEW172
12.1.14BIOGAIA173
TABLE 160BIOGAIA: COMPANY OVERVIEW173
FIGURE 34BIOGAIA: COMPANY SNAPSHOT (2021)174
12.1.15QUANTBIOME, INC. (DBA OMBRE)177
TABLE 161QUANTBIOME, INC.: COMPANY OVERVIEW177
12.2OTHER PLAYERS178
12.2.1VIOME LIFE SCIENCES, INC.178
12.2.2BIOHM HEALTH178
12.2.3DAYTWO179
12.2.4ALTAS BIOMED179
12.2.5BIONE VENTURES PRIVATE LIMITED180
12.2.6LUXIA SCIENTIFIC180
12.2.7METABIOMICS181
12.2.8SUN GENOMICS181
12.2.9SEED HEALTH182
12.2.10GNUBIOTICS SCIENCES182
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13APPENDIX183
13.1KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL186
13.2CUSTOMIZATION OPTIONS188
13.3RELATED REPORTS188
13.4AUTHOR DETAILS189
The human microbiome market has been segmented based on product, type, application, disease, and region.
“By application, the therapeutics segment accounted for the largest share of the human microbiome market”
Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.
“By disease, infectious diseases segment accounted for the largest share in the human microbiome market”
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.
“North America: the largest share of the human microbiome market”
North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.
“Asia Pacific: The fastest-growing region in the human microbiome market.”
The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.
The primary interviews conducted for this report can be categorized as follows:
•By Respondent: Supply Side- 60% and Demand Side 40%
•By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%
•By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%
Prominent Players
•Seres Therapeutics, Inc. (US)
•Enterome (France)
•4D pharma plc (UK)
•International Flavors & Fragrances Inc. (US)
•OptiBiotix Health Plc (UK)
•Ferring Pharmaceuticals (Switzerland)
•Synlogic, Inc. (US)
•Second Genome, Inc. (US)
•Vedanta Biosciences, Inc. (US)
•YSOPIA Bioscience (France)
•FlightPath Biosciences, Inc. (US)
•Finch Therapeutics Group, Inc. (US)
•AOBiome Therapeutics (US)
•BioGaia (Sweden)
•Quantbiome, Inc. (dba Ombre) (US)
•Viome Life Sciences, Inc. (US)
•BIOHM Health (US)
•DayTwo (US)
•Atlas Biomed (UK)
•Bione Ventures Private Limited (India)
•Luxia Scientific (France)
•Metabiomics (US)
•Sun Genomics (US)
•Seed Health (US)
•Gnubiotics Sciences (Switzerland)
Research Coverage:
This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
•Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
•Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
•Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
•Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
•Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.
1INTRODUCTION25
1.1STUDY OBJECTIVES25
1.2MARKET DEFINITION25
1.2.1INCLUSIONS & EXCLUSIONS25
1.3STUDY SCOPE26
1.4YEARS CONSIDERED26
1.5CURRENCY27
1.6RESEARCH LIMITATIONS27
1.7STAKEHOLDERS27
1.7.1RECESSION IMPACT27
2RESEARCH METHODOLOGY28
2.1RESEARCH DATA28
FIGURE 1HUMAN MICROBIOME MARKET: RESEARCH DESIGN28
2.1.1SECONDARY DATA29
2.1.2PRIMARY DATA29
FIGURE 2HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES30
2.2MARKET ESTIMATION METHODOLOGY30
FIGURE 3MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 202331
FIGURE 4HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION)32
FIGURE 5HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029)32
FIGURE 6HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES33
2.3MARKET DATA ESTIMATION AND TRIANGULATION34
2.3.1DATA TRIANGULATION34
FIGURE 7DATA TRIANGULATION METHODOLOGY34
2.4INDUSTRY INSIGHTS35
2.5RESEARCH ASSUMPTIONS35
2.6HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT36
TABLE 1GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)36
TABLE 2US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)36
TABLE 3US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)36
3EXECUTIVE SUMMARY38
FIGURE 8HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)38
FIGURE 9HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)39
FIGURE 10HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION)39
FIGURE 11HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT40
4PREMIUM INSIGHTS41
4.1HUMAN MICROBIOME MARKET OVERVIEW41
FIGURE 12RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH41
4.2NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023)41
FIGURE 13THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 202341
4.3HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES42
FIGURE 14BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD42
5MARKET OVERVIEW43
5.1INTRODUCTION43
5.2MARKET DYNAMICS43
FIGURE 15HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES43
TABLE 4HUMAN MICROBIOME MARKET: IMPACT ANALYSIS44
5.2.1DRIVERS44
5.2.1.1Collaborative efforts between microbiome industry and academia for microbiome research44
5.2.1.2Surging demand for personalized medicine45
5.2.1.3Rising awareness about importance of human microbiome45
5.2.2RESTRAINTS46
5.2.2.1Adverse impact of complex regulatory policies on commercialization of microbiomes46
5.2.3OPPORTUNITIES46
5.2.3.1Increased collaboration of key players and small innovative companies to work on new microbiome technologies46
TABLE 5EXAMPLES OF COMPANY DEVELOPMENT47
5.2.4CHALLENGES48
5.2.4.1Slow patient adoption of microbiome-based therapies48
5.2.4.2Complexities involved in development of microbiome therapies48
5.3TECHNOLOGY ANALYSIS49
5.4TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES51
FIGURE 16TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES51
5.5SUPPLY AND VALUE CHAIN ANALYSIS52
5.5.1HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS52
FIGURE 17HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS52
5.5.2VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET53
FIGURE 18HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS53
5.6ECOSYSTEM ANALYSIS54
FIGURE 19HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS54
5.7PORTER’S FIVE FORCES ANALYSIS54
TABLE 6HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS54
5.7.1THREAT OF NEW ENTRANTS54
5.7.2THREAT OF SUBSTITUTES54
5.7.3BARGAINING POWER OF BUYERS55
5.7.4BARGAINING POWER OF SUPPLIERS55
5.7.5INTENSITY OF COMPETITIVE RIVALRY55
5.8REGULATORY ANALYSIS56
5.8.1FDA APPROVALS56
5.8.2REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 7NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 8EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS56
TABLE 9ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS57
TABLE 10REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS58
5.9PRICING ANALYSIS58
TABLE 11AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT58
5.9.1AVERAGE SELLING PRICE TREND ANALYSIS58
5.10KEY CONFERENCES AND EVENTS IN 202359
5.10.1HUMAN MICROBIOME CONFERENCES (2023)59
TABLE 12HUMAN MICROBIOME CONFERENCES (2023)59
5.11KEY STAKEHOLDERS AND BUYING CRITERIA60
5.11.1KEY STAKEHOLDERS IN BUYING PROCESS60
FIGURE 20HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS60
5.11.2HUMAN MICROBIOME MARKET: BUYING CRITERIA60
FIGURE 21KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS60
6HUMAN MICROBIOME MARKET, BY APPLICATION61
6.1INTRODUCTION62
TABLE 13HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)62
6.2THERAPEUTICS62
6.2.1AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET62
TABLE 14HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION)64
TABLE 15NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)64
TABLE 16EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)64
TABLE 17ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION)65
6.3DIAGNOSTICS65
6.3.1INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET65
TABLE 18HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION)66
TABLE 19NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)66
TABLE 20EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)67
TABLE 21ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION)67
7HUMAN MICROBIOME MARKET, BY DISEASE68
7.1INTRODUCTION69
TABLE 22HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)69
7.2INFECTIOUS DISEASES69
7.2.1RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET69
TABLE 23DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES70
TABLE 24HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION)71
TABLE 25NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)71
TABLE 26EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)71
TABLE 27ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)72
7.3GASTROINTESTINAL DISEASES72
7.3.1SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET72
TABLE 28HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)72
TABLE 29NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
TABLE 30EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
TABLE 31ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)73
7.4ENDOCRINE & METABOLIC DISORDERS74
7.4.1DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET74
TABLE 32DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS74
TABLE 33HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION)75
TABLE 34NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)75
TABLE 35EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)75
TABLE 36ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)76
7.5CANCER76
7.5.1DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET76
TABLE 37HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)77
TABLE 38NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)77
TABLE 39EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)77
TABLE 40ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)78
7.6OTHER DISEASES78
TABLE 41HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION)78
TABLE 42NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)78
TABLE 43EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)79
TABLE 44ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)79
8HUMAN MICROBIOME MARKET, BY PRODUCT80
8.1INTRODUCTION81
TABLE 45HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION))81
8.2DRUGS81
8.2.1GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET81
TABLE 46HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)82
TABLE 47NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)82
TABLE 48EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)82
TABLE 49ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)83
8.3DIAGNOSTIC TESTS83
8.3.1GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET83
TABLE 50HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION)84
TABLE 51NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)84
TABLE 52EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)85
TABLE 53ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)85
8.4PROBIOTICS85
8.4.1GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY85
TABLE 54HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION)86
TABLE 55NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)86
TABLE 56EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)87
TABLE 57ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)87
8.5PREBIOTICS87
8.5.1DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH87
TABLE 58HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION)88
TABLE 59NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)88
TABLE 60EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)89
TABLE 61ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)89
8.6OTHER PRODUCTS89
TABLE 62HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION)90
TABLE 63NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)90
TABLE 64EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)90
TABLE 65ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)91
9HUMAN MICROBIOME MARKET, BY TYPE92
9.1INTRODUCTION93
TABLE 66HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)93
9.2BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)93
9.2.1ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH93
TABLE 67HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION)94
TABLE 68NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)94
TABLE 69EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)94
TABLE 70ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION)95
9.3PEPTIDES95
9.3.1POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET95
TABLE 71HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION)96
TABLE 72NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)96
TABLE 73EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)96
TABLE 74ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION)97
9.4LIVE BIOTHERAPEUTIC PRODUCTS97
9.4.1GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET97
TABLE 75HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION)98
TABLE 76NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)98
TABLE 77EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)98
TABLE 78ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)99
9.5OTHER TYPES99
TABLE 79HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION)99
TABLE 80NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
TABLE 81EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
TABLE 82ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION)100
10HUMAN MICROBIOME MARKET, BY REGION101
10.1INTRODUCTION102
FIGURE 22HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION)102
TABLE 83HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION)102
10.2NORTH AMERICA103
FIGURE 23NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT104
TABLE 84NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)104
TABLE 85NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)105
TABLE 86NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)105
TABLE 87NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)105
10.2.1US106
10.2.1.1Spike in research activities to drive market106
TABLE 88US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)106
TABLE 89US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)107
TABLE 90US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)107
TABLE 91US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)107
10.2.2CANADA108
10.2.2.1Rising prevalence of chronic diseases to boost microbiome research108
TABLE 92CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)108
TABLE 93CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)108
TABLE 94CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)109
TABLE 95CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)109
10.2.3NORTH AMERICA: RECESSION IMPACT109
10.3EUROPE110
TABLE 96EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)110
TABLE 97EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)111
TABLE 98EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)111
TABLE 99EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)111
10.3.1GERMANY112
10.3.1.1Rapid increase in government funding to propel market112
TABLE 100GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)112
TABLE 101GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)112
TABLE 102GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)113
TABLE 103GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)113
10.3.2UK113
10.3.2.1Significant government investments in genomics research to propel growth113
TABLE 104UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)114
TABLE 105UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)114
TABLE 106UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)114
TABLE 107UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)115
10.3.3FRANCE115
10.3.3.1Rise in microbiome sequencing startups to boost growth115
TABLE 108HUMAN MICROBIOME STARTUPS IN FRANCE116
TABLE 109FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)116
TABLE 110FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)117
TABLE 111FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)117
TABLE 112FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)117
10.3.4REST OF EUROPE118
TABLE 113REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)118
TABLE 114REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)118
TABLE 115REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)119
TABLE 116REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)119
10.3.5EUROPE: IMPACT OF RECESSION119
10.4ASIA PACIFIC120
FIGURE 24ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT121
TABLE 117ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)121
TABLE 118ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)122
TABLE 119ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)122
TABLE 120ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)122
TABLE 121ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)123
10.4.1CHINA123
10.4.1.1Increasing R&D investments to drive growth123
TABLE 122CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)124
TABLE 123CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)124
TABLE 124CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)124
TABLE 125CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)125
10.4.2JAPAN125
10.4.2.1Growing geriatric population to present opportunities for market growth125
TABLE 126JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)126
TABLE 127JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)126
TABLE 128JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)126
TABLE 129JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)127
10.4.3INDIA127
10.4.3.1Increasing prevalence of chronic diseases to support growth127
TABLE 130INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)128
TABLE 131INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)128
TABLE 132INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)128
TABLE 133INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)129
10.4.4REST OF ASIA PACIFIC129
TABLE 134REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)129
TABLE 135REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)130
TABLE 136REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)130
TABLE 137REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)130
10.4.5ASIA PACIFIC: RECESSION IMPACT131
10.5REST OF THE WORLD131
TABLE 138REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)131
TABLE 139REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)132
TABLE 140REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)132
TABLE 141REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)132
10.5.1REST OF THE WORLD: RECESSION IMPACT133
11COMPETITIVE LANDSCAPE134
11.1INTRODUCTION134
11.2KEY STRATEGIES ADOPTED BY PLAYERS134
FIGURE 25HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS135
11.3COMPANY EVALUATION QUADRANT136
FIGURE 26HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022)137
11.3.1STARS138
11.3.2EMERGING LEADERS138
11.3.3PERVASIVE PLAYERS138
11.3.4PARTICIPANTS138
11.4COMPANY EVALUATION QUADRANT: START-UPS/SMES139
11.4.1PROGRESSIVE COMPANIES139
11.4.2STARTING BLOCKS139
11.4.3RESPONSIVE COMPANIES139
11.4.4DYNAMIC COMPANIES139
FIGURE 27HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022)140
11.4.5COMPETITIVE BENCHMARKING141
11.4.5.1Human microbiome market: Detailed list of start-ups/SMEs141
TABLE 142HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES141
11.4.5.2Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs)142
TABLE 143HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)142
11.5COMPETITIVE SCENARIO AND TRENDS142
TABLE 144HUMAN MICROBIOME MARKET: DEALS142
11.5.1PRODUCT LAUNCHES144
TABLE 145HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES144
11.5.2EXPANSIONS144
TABLE 146HUMAN MICROBIOME MARKET: EXPANSIONS144
12COMPANY PROFILES145
(Business overview, Products offered, Recent Developments, MNM view)*
12.1KEY PLAYERS145
12.1.1SERES THERAPEUTICS, INC.145
TABLE 147SERES THERAPEUTICS, INC.: COMPANY OVERVIEW145
12.1.2ENTEROME148
TABLE 148ENTEROME: COMPANY OVERVIEW148
12.1.34D PHARMA PLC151
TABLE 1494D PHARMA: COMPANY OVERVIEW151
FIGURE 294D PHARMA: COMPANY SNAPSHOT (2022)151
12.1.4INTERNATIONAL FLAVORS & FRAGRANCES, INC.154
TABLE 150INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW154
FIGURE 30INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022)155
12.1.5OPTIBIOTIX HEALTH PLC157
TABLE 151OPTIBIOTIX: COMPANY OVERVIEW157
FIGURE 31OPTIBIOTIX: COMPANY SNAPSHOT (2021)158
12.1.6FERRING PHARMACEUTICALS162
TABLE 152FERRING PHARMACEUTICALS: COMPANY OVERVIEW162
12.1.7SYNLOGIC, INC.163
TABLE 153SYNLOGIC, INC.: COMPANY OVERVIEW163
FIGURE 32SYNLOGIC, INC: COMPANY SNAPSHOT (2022)163
12.1.8SECOND GENOME INC.165
TABLE 154SECOND GENOME INC.: COMPANY OVERVIEW165
12.1.9VEDANTA BIOSCIENCES, INC.167
TABLE 155VEDANTA BIOSCIENCES: COMPANY OVERVIEW167
12.1.10YSOPIA BIOSCIENCE169
TABLE 156YSOPIA BIOSCIENCE: COMPANY OVERVIEW169
12.1.11FLIGHTPATH BIOSCIENCES, INC.170
TABLE 157FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW170
12.1.12FINCH THERAPEUTICS GROUP, INC.171
TABLE 158FINCH THERAPEUTICS: COMPANY OVERVIEW171
FIGURE 33FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022)171
12.1.13AOBIOME THERAPEUTICS172
TABLE 159AOBIOME THERAPEUTICS: COMPANY OVERVIEW172
12.1.14BIOGAIA173
TABLE 160BIOGAIA: COMPANY OVERVIEW173
FIGURE 34BIOGAIA: COMPANY SNAPSHOT (2021)174
12.1.15QUANTBIOME, INC. (DBA OMBRE)177
TABLE 161QUANTBIOME, INC.: COMPANY OVERVIEW177
12.2OTHER PLAYERS178
12.2.1VIOME LIFE SCIENCES, INC.178
12.2.2BIOHM HEALTH178
12.2.3DAYTWO179
12.2.4ALTAS BIOMED179
12.2.5BIONE VENTURES PRIVATE LIMITED180
12.2.6LUXIA SCIENTIFIC180
12.2.7METABIOMICS181
12.2.8SUN GENOMICS181
12.2.9SEED HEALTH182
12.2.10GNUBIOTICS SCIENCES182
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13APPENDIX183
13.1KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL186
13.2CUSTOMIZATION OPTIONS188
13.3RELATED REPORTS188
13.4AUTHOR DETAILS189
Related Report
